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Introduction
Preeclampsia is a common and serious hypertensive disorder 
affecting approximately 5% of pregnancies. The underlying biol-
ogy of the disease is complex and not fully understood (1). Poor 
invasion of the placenta, characterized by incomplete remodeling 
of uterine spiral arteries early in pregnancy, is thought to promote 
the altered production of placenta-derived factors in the latter half 
of pregnancy in response to hypoxia that results from the vascu-
lar remodeling defect (2–4). These factors induce maternal endo-
thelial activation and inflammation, which manifest clinically as 
hypertension and varying degrees of end-organ injury. Significant 
attention has been given to the role of the circulating angiogenic 
factors soluble fms-like tyrosine kinase-1 (sFlt-1, also known as soluble 
VEGFR-1) and placental growth factor (PlGF) in this process as well as 
their potential utility as early biomarkers of the disease (5–8). In pre-
eclampsia, elevated sFlt-1 — a truncated, soluble form of Flt-1 lacking 
the tyrosine kinase domain — acts as a decoy receptor, functioning 
as a molecular sponge to limit signaling induced by elevated levels of 
circulating proangiogenic ligands and preventing their action on tar-
get cells (9–11). In rodents, adenovirus-mediated overexpression of 
sFlt-1 or treatment with anti-VEGF antibodies or recombinant sFlt-1 
induces hypertension, proteinuria, and kidney glomerular injury in 
pregnancy (11–13). These observations provided the foundation for 
a widely accepted model for preeclampsia in which an angiogenic 
factor imbalance, characterized by an abnormally high ratio of sFlt-1 
to PlGF and VEGF, is thought to be an essential component of 
disease pathogenesis (reviewed in refs. 1, 2, 14).
PlGF, a member of the VEGF family, was originally discov-
ered in the placenta, where it was proposed to regulate vascular 
development and trophoblast growth and differentiation (15). 
Unlike VEGF, which is required for angiogenesis and endothelial 
cell maintenance and binds both Flt-1/sFlt-1 and Flk-1, PlGF is 
redundant for vascular development and selectively binds Flt-1/
sFlt-1 (16–18). PlGF stimulates endothelial cell growth, migration, 
and survival and plays a central role in pathologic angiogenesis, 
including in cancer and tissue ischemia (19, 20). In addition to sig-
naling through Flt-1, PlGF promotes angiogenesis by competing 
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phenotype (37). Additional findings consistent with preeclampsia 
have been reported in various studies of pregnant COMT-deficient 
mice, including fetal growth restriction (37, 38), abnormal uterine 
artery Doppler waveforms (38), an exaggerated response to angio-
tensin II (39), and an abnormal metabolome (40). We hypothesized 
that PlGF deficiency would induce a preeclampsia-like phenotype 
by promoting an antiangiogenic state defined by excess sFlt-1 and 
that loss of PlGF in the setting of COMT deficiency would exac-
erbate the phenotype. Our findings, however, suggest that PlGF is 
protective against the development of preeclampsia-like features 
in COMT KO mice and that placental PlGF plays a role in normal 
placental development and metabolism.
Results
Loss of PlGF in pregnancy results in elevated sFlt-1 levels. We used mice 
with genetic deletion of PlGF (Pgf–/–; PlGF KO) to evaluate the effect 
of PlGF deficiency on serum angiogenic factor levels in pregnancy. 
PlGF expression examined by immunofluorescence was confirmed 
in placentas of WT mice, but not PlGF KO mice, with expression 
primarily in parietal trophoblast giant cell and spongiotrophoblast 
populations, consistent with prior studies (data not shown; refs. 
21, 24). Serum VEGF and sFlt-1 levels were measured in PlGF KO 
and WT mice by ELISA and were found to be elevated in pregnant 
compared with nonpregnant mice, as expected (Figure 1, A and B). 
Whereas serum VEGF levels in pregnant KO and WT mice were sim-
ilar (Figure 1A), sFlt-1 levels were significantly elevated in pregnant 
PlGF KO mice compared with pregnant WT (Figure 1B). Immunos-
taining for Flt-1 revealed increased Flt-1 expression in the junctional 
zone spongiotrophoblasts, parietal trophoblast giant cells, and asso-
with VEGFA for Flt-1, freeing VEGFA to signal through Flk-1 (17). 
PlGF is upregulated in pregnancy, with levels peaking in the serum 
of pregnant women in the early third trimester (10, 21, 22). In preg-
nant mice, PlGF has been shown to influence maternal cardiovas-
cular physiology (23). In the placenta, it is expressed in trophoblast 
giant cells and decidual natural killer cells (21, 24). Although it is 
dispensable for embryogenesis (16), recent data support its func-
tion in fetal cerebrovascular development (25). Despite interest in 
the utility of PlGF for clinical diagnostics, the role of PlGF in pre-
eclampsia and in placental development is not well understood.
To delineate the pathogenic role of sFlt-1 and PlGF in pre-
eclampsia, we used PlGF KO mice to create an angiogenic factor 
imbalance in pregnancy. We also examined the role of PlGF in pre-
eclampsia by generating mice with genetic deletion of both PlGF 
and the enzyme catechol-O-methyltransferase (COMT). Reduced 
COMT activity and low plasma levels of its metabolic product, 
2-methoxyestradiol (2-ME), are observed in preeclampsia (26–32). 
Mechanistically, 2-ME has been shown to promote extravillous tro-
phoblast invasion (33) and migration (29) and to dysregulate HIF-
1α function (34–36). Treatment of first trimester placental villous 
explants with 2-ME rescued altered levels of sFlt-1 and hypoxia- 
inducible factor 1-α (HIF-1α) induced by hypoxia (36). We pre-
viously reported that pregnant COMT KO mice develop a pre-
eclampsia-like phenotype characterized by hypertension, protein-
uria, renal glomerular endotheliosis, increased placental hypoxia, 
an influx of decidual natural killer cells, and elevated circulating 
sFlt-1 (37). Treatment of pregnant COMT KO mice with 2-ME res-
cued the preeclampsia-like phenotype, while treatment of WT mice 
with an inhibitor of COMT (Ro41-0960) mimicked the COMT KO 
Figure 1. Elevation of serum sFlt-1 
and placental Flt-1 levels in pregnant 
PlGF KO mice. (A) Serum VEGF levels 
measured by ELISA in nonpregnant WT 
(n = 6) and PlGF KO (n = 9) and pregnant 
WT (n = 10) and PlGF KO (n = 10) mice. (B) 
Serum sFlt-1 levels (ELISA) in nonpreg-
nant and pregnant WT (n = 4) and PlGF 
KO (n = 5) mice. (C) Immunohistochemis-
try for Flt-1 shows increased Flt-1 protein 
expression in PlGF KO placentas and 
decidua compared with WT. Spongiotro-
phoblast cells marked by yellow aster-
isks, parietal trophoblast giant cells by 
yellow arrowheads. Solid lines mark the 
border between the junctional zone and 
the decidua. D, decidua; JZ, junctional 
zone. Scale bars: 100 μm (top row); 25 μm 
(bottom row). (D) Immunohistochemistry 
for Flt-1 in the kidney glomerulus show-
ing similar expression in PlGF KO and WT 
(upper panels). Secondary antibody–only 
control shown in lower panels. Scale bars: 
25 μm. Results are shown as mean ± 
SD. One-way ANOVA. **P < 0.01, ***P < 
0.001, ****P < 0.0001.
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analyses of the maternal kidneys revealed normal kidney architec-
ture in pregnant PlGF KO mice (Figure 2I). Detailed examination 
of glomerular structure also showed a similar number of cells per 
glomerulus (Figure 2H) and no differences in renal corpuscle, glo-
merular tuft, or Bowman’s space areas (Supplemental Figure 2, A 
and B). Transmission electron microscopy (Figure 2J) and scanning 
electron microscopy (Figure 2K) analyses revealed intact podo-
cyte foot processes and absence of glomerular endotheliosis and 
hyperproliferation, indicating normal glomerular ultrastructure in 
pregnant PlGF KO mice. Collectively, these results show that PlGF 
KO mice do not show manifestations of preeclampsia despite an 
abnormal elevation in circulating sFlt-1.
PlGF KO placentas exhibit increased junctional zone glycogen 
and decreased labyrinth area. The mouse placenta is divided into 
3 compartments: the decidua on the maternal side, the middle 
junctional zone, and the vessel-dense labyrinth layer on the fetal 
side. Alterations in the overall placental architecture were evident 
on histological analyses of H&E-stained cross-sections, which 
revealed a significantly thicker junctional zone and thinner laby-
rinth layer in PlGF KO placentas (Figure 3, A and D). Expansion 
of the junctional zone appeared to be due primarily to increased 
numbers of vacuolated glycogen trophoblast cells (Figure 3A). 
Glycogen accumulation in PlGF KO placentas was confirmed 
ciated decidua of KO placentas (Figure 1C and Supplemental Figure 
1, A and B; supplemental material available online with this article; 
https://doi.org/10.1172/JCI99026DS1), but not in the kidneys of 
PlGF KO mice (Figure 1D). These results suggest that the elevated 
circulating sFlt-1 levels in pregnant PlGF KO mice originated from 
increased placental Flt-1 expression.
Pregnant PlGF KO mice do not develop signs of preeclampsia. 
Hypertension and proteinuria, the classic features of preeclamp-
sia, were evaluated in pregnant PlGF KO and WT mice. Tail-cuff 
blood pressures measured at E17–E20 were similar for PlGF KO 
and WT mice (Figure 2A), as were urine albumin/creatinine 
ratios (Figure 2B). Preeclampsia is also associated with increased 
rates of fetal growth restriction and fetal demise due to placental 
insufficiency. Therefore, we compared the litter sizes, resorption 
rates, and embryonic weights and found no significant differ-
ences between KO and WT mice (Figure 2, C–E). These findings 
are in concordance with the previously reported normal fertility 
and litter size of PlGF KO mice (16, 23). The embryo/placenta 
ratio was significantly decreased in PlGF KO compared with WT 
(Figure 2G) due to increased placental weight in PlGF KO mice 
(Figure 2F and Supplemental Table 1).
Glomerular capillary endotheliosis and podocyte injury are sig-
nature kidney lesions associated with preeclampsia. Histological 
Figure 2. Pregnant PlGF KO mice do not develop signs or complications of preeclampsia. (A) Systolic blood pressure (BP) of pregnant WT (n = 5) and PlGF KO 
(n = 4) mice. (B) Proteinuria measured by spot urine albumin/creatinine (Cr) ratios for pregnant WT (n = 8) and KO mice (n = 11). Blood pressure and urine pro-
tein measured between E17 and E20. (C) Total number of embryos per litter, includes resorbing embryos (n = 10 litters). (D) Percentage of resorbed embryos 
per litter (n = 10 litters). (E–F) Weights of individual embryos (E) and placentas (F) from WT (n = 63 embryos/placentas from 7 litters) and KO (n = 40 embryos/
placentas from 4 litters) mice collected between E17 and E20. (G) Embryo/placenta ratio decreased in PlGF KO (n = 40 embryos from 4 litters) compared with 
WT (n = 62 embryos from 7 litters). (H) Number of nuclei per glomerulus (n = 3 mice, 6–10 glomeruli per mouse). (I) Representative images of H&E-stained 
kidney sections from the indicated groups showing normal tubules and glomeruli. Scale bars: 100 μm; 50 μm (inset). (J) Normal podocyte foot processes, 
glomerular basement membrane, and slit diaphragms by transmission electron microscopy and (K) normal podocyte foot processes by scanning electron 
microscopy for both groups. Scale bars: 1 μm (J); 5 μm (K). Results are shown as mean ± SD. Two-tailed, unpaired t test. *P < 0.05.
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phenotype (37). PlGF KO and COMT KO mice were bred to gen-
erate double KO (DKO) mice (Pgf–/–; Comt–/–). DKO females were 
mated to COMT KO males (DKOxPlGF+) or DKO males (DKOxDKO) 
to assess the role of placental PlGF on the maternal preeclamp-
sia phenotype. This mating scheme produced pregnancies with 
placentas expressing (Pgf +/-; Comt–/–, placental PlGF+/–) or lacking 
(Pgf–/–; Comt–/–, placental PlGF–/–) PlGF, respectively (Figure 4A). 
Lack of placental PlGF in pregnant DKOxDKO mice was associated 
with a lower systolic blood pressure (Figure 4B) and a trend toward 
decreased proteinuria (Figure 4C) when compared with DKOxPlGF+ 
pregnant females, indicating partial rescue of the preeclampsia 
phenotype caused by COMT deficiency. The relative reduction in 
blood pressure in pregnant DKO mice lacking placental PlGF was 
associated with a nonsignificant elevation of sFlt-1 compared with 
that in pregnant DKOxPlGF+ mice (Figure 4D), in which sFlt-1 levels 
approximate the levels observed in the COMT KO model of pre-
eclampsia. Blood pressure, proteinuria, and sFlt-1 data for PlGF, 
COMT, and DKO mice are summarized in Supplemental Table 
2. Similarly to PlGF KO litters, which show a decreased embryo/ 
placenta ratio, DKOxDKO litters also showed a decreased embryo/
placenta ratio (Figure 4G and Supplemental Table 1), which 
appeared to be driven by a significant reduction in embryonic 
weight (Figure 4E), as placental weight was not dependent on the 
PlGF genotype (Figure 4F).
Based on the findings in PlGF KO placentas, we anticipated 
that PlGF loss would lead to an increase in glycogen content 
with the glycogen-specific stain Best’s carmine (Figure 3B) and 
quantification of tissue glycogen content (Figure 3E). Parietal tro-
phoblast giant cells (demarcating the junctional zone-decidual 
border) and spongiotrophoblasts in the junctional zone appeared 
normal in PlGF KO placentas (Supplemental Figure 3, A and B).
We next examined the labyrinth layer, which comprises a dense 
network of fetal and maternal blood vessels. Comparisons of PlGF 
KO with WT placentas revealed a similar density of endothelial 
cell–lined fetal vessels identified by CD34 immunohistochemistry 
(Figure 3, C and F). Mononuclear sinusoidal trophoblast giant cells 
lining the maternal vessels had normal morphology by H&E (Sup-
plemental Figure 3C) and pan-cytokeratin staining (Supplemental 
Figure 3D). Overall, labyrinth vessel architecture was similar in 
PlGF KO and WT placentas, but labyrinth area in PlGF KO placen-
tas was decreased compared with that in WT (Figure 3D). These 
placental changes were associated with increased placental weight 
in PlGF KO mice (Figure 2F). Collectively, these results show that 
PlGF loss leads to junctional zone glycogen accumulation, a reduc-
tion in labyrinth area, and a larger placenta, but does not signifi-
cantly affect trophoblast morphology or labyrinth architecture.
Loss of PlGF ameliorates the preeclampsia-like phenotype in 
COMT-deficient mice. Since we observed an increase in sFlt-1 levels 
and a placental phenotype in PlGF KO mice, but an absence of pre-
eclampsia manifestations, we hypothesized that loss of PlGF might 
be protective. We tested the effects of PlGF loss in preeclampsia 
using the COMT KO model, which develops a preeclampsia-like 
Figure 3. Changes in morphology and glycogen content in PlGF KO placentas. (A) Representative low- and high-magnification images of H&E-stained 
cross-sections of placentas showing increased numbers of junctional zone glycogen trophoblast cells, which appear as islets of cells with clear cytoplasm 
due to the high content of glycogen-containing vacuoles. Scale bars: 500 μm (low); 100 μm (high). (B) Specific staining of glycogen with Best’s carmine 
(red) in the junctional zone (E19). Scale bars: 200 μm (low); 50 μm (high). Solid and dotted lines mark the borders between the junctional zone and the 
decidua and junctional zone and labyrinth, respectively. (C) Immunohistochemistry for CD34 showing similar staining of fetal vasculature in the labyrinth. 
Scale bars: 100 μm (low); 50 μm (high). (D) Quantification of placental layer measurements expressed as a proportion of total placental thickness. At least 
2 midplacental cross sections were analyzed from each placenta from WT (n = 21 placentas from 7 litters) and KO (n = 38 placentas from 5 litters) mice. (E) 
Quantification of relative glycogen content (μg glycogen/mg placental tissue) in WT (n = 3) and KO (n = 9) placentas. (F) Quantification of CD34 staining (% 
positive area) of the labyrinth in WT and KO placentas (n = 3 placentas from 3 litters, 3 representative high-power fields per placenta) L, labyrinth. Results 
are shown as mean ± SD (D, E) and mean ± SEM (F). Two-tailed, unpaired t test. *P < 0.05; ****P < 0.0001.
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Thus, we examined placental expression of basement membrane 
proteins laminin and entactin (also known as nidogen-1) in DKO 
and COMT KO placentas. Both proteins were more abundant in 
PlGF-expressing placentas from DKOxPlGF+ compared with DKOxDKO 
mice by immunofluorescence (Supplemental Figure 6A). Consis-
tent with this finding, increased staining of these basement mem-
brane proteins was observed in COMT KO placentas compared with 
WT or COMT KO treated with 2-ME (Supplemental Figure 6B). In 
summary, we have shown that PlGF loss in the COMT KO pre-
eclampsia model leads to increased glycogen content and reduced 
basement membrane protein deposition in the placenta, which 
were associated with a reduction in maternal blood pressure and 
alterations in embryonic growth.
Correlation between PlGF and 2-ME in plasma from preeclamp-
tic women. In the COMT KO mouse, low levels of 2-ME (metab-
olite of COMT enzyme activity) are associated with placental 
hypoxia and increased HIF-1α expression (37). Because low PlGF 
levels are also strongly associated with placental hypoxia and pre-
eclampsia, we evaluated the relationship between PlGF and 2-ME 
in DKOxDKO placentas. At baseline, COMT KO mice exhibited 
decreased placental glycogen that was rescued with 2-ME treat-
ment (Supplemental Figure 4, A and B). In the DKO context, this 
loss of glycogen in COMT-deficient placentas was represented 
in the DKOxPlGF+ mice, which showed a comparable percentage of 
glycogen-positive cells in the junctional zone compared with 
COMT KO mice (Figure 4H and Supplemental Figure 4B). The 
glycogen content in DKOxDKO placentas lacking PlGF was indeed 
increased compared with that in DKOxPlGF+ placentas, confirmed 
by Best’s carmine stain, indicating partial rescue of the reduced 
glycogen phenotype seen in COMT KO placentas (Figure 4, H and 
I). In preeclamptic women, alterations in placental glycogen con-
tent have previously been reported (41–43). This was confirmed in 
our study by measuring tissue glycogen content in human placen-
tas from normotensive control versus preeclamptic pregnancies 
(Supplemental Figure 5A).
Thickening of the basement membrane has also been assoc-
iated with preeclampsia and other conditions of placental insuffi-
ciency, such as hypertension and fetal growth restriction (44, 45). 
Figure 4. Loss of PlGF ameliorates preeclampsia-like phenotype in COMT KO mice. (A) Schematic of the breeding strategy and embryo/placenta geno-
types. (B) Systolic blood pressure in nonpregnant DKO (Pgf–/–; Comt–/–; n = 9) and pregnant DKOxPlGF+ (n = 5) and DKOxDKO (n = 9) mice at E17. (C) Proteinuria 
measured by spot urine albumin/creatinine ratio (n = 6). (D) Plasma sFlt-1 measured by ELISA in nonpregnant DKO (n = 3), DKOxPlGF+ (n = 5), and DKOxDKO  
(n = 6) at E17. (E–F) Weights of embryos (E) and placentas (F) collected at E17 from DKOxPlGF+ (n = 38 embryos from 5 litters) and DKOxDKO (n = 52 embryos 
from 7 litters) cohorts. (G) Embryo/placenta ratio decreased in DKOxDKO (placental PlGF–/–). (H) Representative images of the placenta and of the junctional 
zone showing Best’s carmine glycogen staining of E17 placentas. Solid and dotted lines mark the borders between the junctional zone and the decidua and 
the junctional zone and labyrinth, respectively. Scale bars: 100 μm (top row); 25 μm (bottom row). (I) Ratio (%) of glycogen-positive cells to total junctional 
zone cells per visual field (n = 5 placentas). (J) Linear regression analysis of the relationship between plasma PlGF and 2-ME levels in preeclampsia (human 
cases; n = 17). PlGF samples here are also represented in Supplemental Figure 5C. NP, nonpregnant. Results are shown as mean ± SD. One-way ANOVA 
(B–D), 2-tailed, unpaired t test (E–H), or Pearson’s correlation test (J). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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levels in human plasma. First, we validated previous findings by 
our group and others showing reduced 2-ME (26–29, 31, 32) and 
PlGF levels (6, 10, 11) in preeclamptic compared with control 
women (Supplemental Figure 5, B and C). Then we assessed their 
relationship in patient plasma and found a significant positive, 
linear correlation between PlGF and 2-ME among women with 
preeclampsia (Figure 4J).
Discussion
Numerous studies have established the association between an 
elevated sFlt-1/PlGF ratio and preeclampsia (5, 10, 11, 46–49). 
However, whether this biochemical imbalance is directly related 
to disease etiology remains largely unknown. We studied mice 
with genetic deletion of PlGF to address whether the resultant 
angiogenic factor imbalance would be sufficient to induce pre-
eclampsia. We found that pregnant PlGF KO mice displayed an 
abnormally elevated level of circulating sFlt-1, but lacked mani-
festations of preeclampsia, in contrast with mice lacking COMT, 
despite a mean serum concentration of sFlt-1 that was greater 
than peak concentrations observed in human preeclampsia and 
in other rodent models of preeclampsia (10, 11). Upregulation 
of placental Flt-1 and sFlt-1 receptors was presumed to occur in 
response to ligand depletion. Notably, loss of placental PlGF in 
the COMT KO preeclampsia model ameliorated the maternal 
hypertension phenotype of those mice. Furthermore, deletion of 
PlGF altered placental morphology, supporting a role for PlGF in 
placental development.
Our study demonstrated that PlGF KO placentas have a dis-
tinct morphology characterized by enlargement of the junctional 
zone due to glycogen accumulation and a reduction in the area 
of the labyrinth compartment. Glycogen trophoblasts, a popula-
tion of specialized trophoblast cells found in the junctional zone 
and decidua, are rich in glycogen-containing vacuoles and have 
been compared with invasive extravillous cytotrophoblasts of 
the human placenta (50, 51). Although the primary purpose of 
placental glycogen is a matter of debate, it is thought to serve as 
an important energy source for fetal growth and can be utilized 
to maintain placental function under hypoxic conditions (51–55). 
Many studies have reported alterations in placental metabolism 
and glycogen content in preeclampsia and fetal growth abnormal-
ities in human and rodent pregnancy, although it is challenging 
to make definitive conclusions from these studies due to sample 
and methodological differences (41–43, 51, 56). What is evident is 
that the significance of increased placental glycogen alterations is 
context dependent, for instance, indicating excess nutrient avail-
ability in diabetes as opposed to impaired utilization or compensa-
tion for placental dysfunction in preeclampsia. There is evidence 
that increased glycogen may serve a protective function. In cancer 
cells, for example, increases in cellular glycogen storage have been 
shown to maintain cellular ATP levels as a protective mechanism 
against bioenergetic stress (57). In genetic mouse models, pla-
cental glycogen has been shown to play a role in preserving fetal 
growth (53). Furthermore, increased placental glycogen in human 
preeclampsia cases was reported in conjunction with a significant 
increase in placental glycogen synthase activity, suggesting a met-
abolic state favoring glycogen synthesis in preeclampsia (41). Col-
lectively, the literature suggests that placental glycogen effectively 
acts as a barometer for disturbances in fetoplacental metabolism 
and that its availability may be an important etiologic component 
of some pregnancy conditions and a consequence of others.
We found that loss of PlGF in both WT and COMT KO back-
grounds resulted in a significant increase in placental glycogen 
and a reduction in the embryo/placenta ratio, a parameter used 
as a rough proxy for placental function (58, 59). We speculate that 
this phenotype represented a compensatory response to distur-
bances in placental function that have been documented in the 
COMT-deficient background (37), and are inferred in the PlGF–
single KO model based on increased sFlt-1 levels and the reduc-
tion in labyrinth area, which directly affects placental nutrient 
exchange capacity. The placental phenotype resulting from PlGF 
loss had a net beneficial effect for the mother, demonstrated by 
the absence of preeclampsia in pregnant PlGF KO mice and a 
reduction in blood pressure in pregnant DKOxDKO. The change in 
labyrinth area was not entirely surprising, given the established 
role of PlGF in angiogenesis. Based on our histologic findings and 
the localization of Flt-1 receptor to trophoblasts residing in the 
junctional zone and at the decidual border (i.e., glycogen tropho-
blast cells, spongiotrophoblast cells, and endovascular trophoblast 
cells), we postulate that the location of PlGF action in the placenta 
is primarily the junctional zone (60). Whether PlGF directly regu-
lates the activity of key enzymes involved in glycogen metabolism 
or whether additional mechanisms of compensation, such as local 
upregulation of VEGF, occurred is not known; these are areas of 
interest for future studies. Our findings suggest that PlGF loss had 
a protective effect potentially mediated through alterations in pla-
cental metabolism, which strongly correlates with placental glyco-
gen content and preeclampsia (41, 42, 51, 56, 61, 62).
In plasma samples from preeclamptic women, we found a 
significant positive correlation between levels of 2-ME and PlGF. 
Reduced COMT activity and 2-ME have consistently been asso-
ciated with preeclampsia and placental hypoxia and metabolism 
(29, 37, 40, 62–64). We speculate that suppression of PlGF in the 
context of low 2-ME levels in preeclampsia might promote pla-
cental glycogen accumulation as an adaptive response to mitigate 
oxidative stress. The COMT KO mouse has decreased placental 
glycogen content (Supplemental Figure 4, A and B), which at first 
seemed to contradict this proposed relationship between sup-
pressed 2-ME/PlGF and increased placental glycogen. However, 
measurements of PlGF levels revealed that PlGF is not suppressed 
in COMT KO mice compared with WT (Supplemental Figure 4C). 
Therefore, differences in PlGF levels may partially explain the 
relative lack of placental glycogen in COMT KO mice compared 
with PlGF KO mice and human preeclampsia. Deletion of PlGF 
in COMT mice (DKOxDKO) did indeed result in increased placen-
tal glycogen, lending further support to potential coordinated or 
overlapping roles for PlGF and 2-ME in regulating placental glyco-
gen and metabolism in preeclampsia.
Despite significant interest in PlGF as a predictor and diag-
nostic biomarker of preeclampsia (5, 6, 65), the precise role of 
PlGF in the placenta and preeclampsia is not well understood. 
A recent study by Aasa and colleagues examined the effect of 
PlGF loss on maternal cardiovascular physiology (23). Pregnant 
PlGF KO mice were found to have changes in systolic blood pres-
sure, cardiac output, ventricular mass, and expression of cardiac 
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stress-related genes in addition to a mild renal phenotype at E16. 
Alterations in maternal cardiac parameters occurred at E14 and 
E16 and normalized by E18, leading the authors to propose a lim-
ited window for PlGF activity during pregnancy with respect to 
maternal cardiovascular adaptations. Early transient increased 
uterine artery resistance was reported in PlGF KO mice; this did 
not have a significant impact on fetal blood flow (by umbilical 
artery Doppler), fetal/neonatal growth, or litter size, consistent 
with our litter data. Any discrepancies between our studies can 
likely be explained by differences in study design and meth-
odology. We focused our evaluation late in gestation, when 
preeclampsia occurs most commonly; Aasa et al. highlighted 
a maternal phenotype that was evident at earlier time points 
than the ones we examined (23). Although they reported a dif-
ference in blood pressure in PlGF KO mice compared with WT 
C57BL/6, the absolute difference in blood pressure at the late 
time points of gestation was minimal and not inconsistent with 
our results. Variations in blood pressure may also be due to dif-
ferences in genetic background of the mice. Importantly, our 
studies had different objectives and therefore report outcomes 
that are not mutually exclusive.
We acknowledge that the PlGF KO model does not faithfully 
recapitulate the pattern seen in preeclampsia in which PlGF is 
reduced but still present. The existence of 4 PlGF splice variants 
in human compared with only 1 variant in mouse also suggests 
more complex PlGF biology and function in humans that remains 
to be explored in the context of preeclampsia (66). Furthermore, 
PlGF is a pleiotropic factor implicated in blood pressure regulation 
via the renin-angiotensin-aldosterone system (67, 68). This inter-
action was beyond the scope of our study, but may be relevant to 
the pathogenesis of preeclampsia (39, 69–72). Finally, the impact 
of local angiogenic factors, particularly VEGF, is an area of inter-
est for future studies, as there is evidence that local regulation of 
angiogenic factors at the maternal-fetal interface is important for 
the maintenance of vascular integrity in the placenta (73).
Importantly, an elevated sFlt-1/PlGF ratio is not a prereq-
uisite for the development of preeclampsia, nor is it unique to 
preeclampsia. As proposed in a recent review, elevated sFlt-1 
and reduced PlGF levels may represent placental cellular stress 
or failure of homeostatic mechanisms in general, rather than 
preeclampsia per se (3). A similar profile of angiogenic factors is 
observed in a host of other conditions associated with compro-
mised placental function (74), including fetal growth restriction 
(75, 76), fetal death (77, 78), multiple gestation (79, 80), system-
ic lupus erythematosus (81), and pregnancies resulting from in 
vitro fertilization (82). Our findings support a complex and multi-
faceted model for the pathogenesis of preeclampsia, consistent 
with the current consensus that preeclampsia is a syndrome with 
multiple etiologies Therefore, designating a single pathophysi-
ologic model is not accurate (61). Therapeutic approaches have 
been proposed based on the idea that attenuating the antian-
giogenic environment in preeclampsia will improve clinical sta-
tus and delay disease progression (13, 83, 84). However, studies 
revealing disease-promoting functions of PlGF (85–89) support 
the need for further mechanism-focused research, and therefore, 
interventions aiming to alter angiogenic factors in preeclampsia 
should be approached with caution. Here, we provide evidence 
for the broader impact of PlGF on placental development, poten-
tially via regulation of fetal-placental metabolism.
Methods
Mice. PlGF KO mice (Pgf–/–; mixed background, Swiss/SV129) were 
previously generated by deletion of exons 3–6 (16) and provided 
by P. Carmeliet. Homozygous adult PlGF KO and WT matings pro-
duced pregnant females carrying litters of PlGF KO and WT embry-
os, respectively. Pgf–/–; Comt–/– DKO mice were generated by breeding 
COMT KO (mixed, C57BL/6/SV129) and PlGF KO (mixed, Swiss/
SV129) mice. DKO females were bred to either DKO males (DKOxDKO) 
or COMT KO males (DKOxPlGF+) to produce pregnancies with DKO 
(Pgf–/–; Comt–/–) embryos and PlGF-positive (Pgf +/-; Comt–/–) embry-
os, respectively. For COMT KO experiments, pregnant COMT KO 
and WT mice were injected subcutaneously daily with 10 ng 2-ME 
(Sigma-Aldrich) or placebo (olive oil), respectively, starting from 
E10, as previously described (37). The day the vaginal plug was 
observed was taken to be 12 hours after fertilization and set as E0.5.
ELISA, urinary protein, and blood pressure measurements. Blood 
and urine samples were collected from nonpregnant and pregnant 
PlGF KO and WT mice between E17 and E20 and from DKOxDKO 
and DKOxPlGF+ mice at E17. Serum or plasma sFlt-1, VEGF, and PlGF 
levels were measured using Quantikine ELISA kits (R&D Systems). 
Urine protein levels were estimated using a colorimetric assay (Sigma- 
Aldrich), as previously described (12). Blood pressure was monitored 
using a programmable tail-cuff sphygmomanometer (SC-1000, Hat-
teras Instruments), as previously described (37).
Embryo and placental measurements. Pregnant mice were sac-
rificed at the time points indicated above. Weights of placentas and 
embryos were recorded. Embryonic demise was calculated by the 
number of resorptions divided by the total number of embryos for 
each pregnancy.
Histology. Animals were perfusion fixed with 4% paraformal-
dehyde in 0.1 M phosphate buffer. Paraffin-embedded organs were 
sectioned (5 μm) and used for H&E staining, immunohistochemistry, 
and immunofluorescence. H&E-stained cross-sections from the mid-
portion of the placenta were analyzed for trophoblast morphology 
and junctional zone/labyrinth architecture. Placental layers were 
measured to determine the relative thickness of the junctional zone 
and labyrinth, which was expressed as a proportion of total placen-
tal thickness. For histological analysis of kidney, randomly selected 
glomeruli were identified and quantified by counting the number of 
nuclei per 6 to 10 glomeruli per kidney. Areas of the renal corpuscle 
and glomerular tuft were quantified with ImageJ (NIH). The area of 
Bowman’s space was calculated by subtracting glomerular tuft area 
from renal corpuscle area.
Immunohistochemistry and immunofluorescence. For immunohis-
tochemistry, sections were deparaffinized and rehydrated, and anti-
gen was retrieved at 98°C for 30 minutes in 10 mM citrate buffer, 
pH 6. Sections were incubated with blocking buffer, followed by pri-
mary antibody. The following primary antibodies were used: Flt-1 
(Santa Cruz Biotechnology Inc., catalog sc-9029, 1:100; Abcam, cat-
alog ab2350, 1:100); CD34 (Abcam, catalog ab81289, 1:500). Pla-
cental Flt-1 staining was processed using a VECTASTAIN ABC Kit 
(Vector Laboratories). For all other stains, sections were incubated 
with 4plus Biotinylated Goat Anti-Rabbit Secondary Antibody and 
streptavidin-HRP (BioCare Medical), followed by DAB peroxidase 
. 
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figure legends to determine significance. Statistical significance 
was defined as P < 0.05. GraphPad Prism 6 software was used for 
statistical analyses.
Study approval. All animal experiments were approved by the Beth 
Israel Deaconess Medical Center Institutional Animal Care and Use 
Committee. Studies involving human specimens were approved by 
the University of Pennsylvania, Mayo Clinic, and Brigham and Wom-
en’s Hospital Institutional Review Boards. Written, informed consent 
was obtained from subjects prior to inclusion in the study.
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substrate reagent. Sections were counterstained with hematoxylin, 
and DAB positivity was analyzed. Immunofluorescence analysis of 
frozen sections was performed as previously described (37). The fol-
lowing primary antibodies were used: Flt-1 (Abcam, catalog ab2350, 
1:100); pan-cytokeratin (Sigma-Aldrich, catalog C1801, 1:200); 
laminin (Sigma-Aldrich, catalog L9393, 1:200); and entactin (also 
known as nidogen-1, Chemicon International, catalog MAB1946, 
1:100). For quantification of CD34 and Flt-1, 3 visual fields were 
analyzed per placenta using ImageJ.
Electron microscopy of the kidney. Kidney tissues were fixed with 
2.5% glutaraldehyde, 2% paraformaldehyde in 0.1 M cacodylate buffer. 
Kidney segments were processed for electron microscopy and viewed 
with an FEI Tecnai G2 Biotwin transmission electron microscope or a 
JEOL 6390 scanning electron microscope, as previously described (90).
Placental glycogen measurements. Best’s carmine was used to stain 
placental glycogen. Deparaffinized sections were incubated for 20 
minutes in Best’s carmine staining solution, followed by differentia-
tion solution and dehydration. Amylase treatment was used to evalu-
ate the specificity of Best’s carmine staining of glycogen.
Glycogen content was quantified by either digestion and precipita-
tion from placental tissue or imaging of Best’s carmine–stained sections. 
For tissue digestion, portions of placental tissue were weighed and boiled 
in 30% potassium hydroxide, 5% sodium sulfate bath for 30 minutes to 
release the glycogen. After cooling on ice, glycogen was precipitated 
with 1.1 volumes of 95% ethanol. Glycogen precipitates were dissolved 
in water and analyzed by a phenol sulfuric acid colorimetric method 
(91). Calculated glycogen content was normalized to the weight of the 
starting tissue and expressed as μg/glycogen per mg placental tissue. 
For quantification of glycogen cells by imaging, the number of glycogen- 
positive cells (by Best’s carmine staining) per visual field was counted 
and expressed as a percentage of total cells in the junctional zone.
Human sample collection and measurement of PlGF and 2-ME levels. 
Blood samples from preeclampsia cases and normotensive controls 
were collected from patients at the University of Pennsylvania (pro-
vided by SP and JFS), Mayo Clinic (provided by VDG), and Brigham 
and Women’s (provided by TFM) Hospitals. Preeclampsia was diag-
nosed according to American College of Obstetricians and Gynecol-
ogists criteria (92). PlGF levels were measured using a Quantikine 
ELISA Kit (R&D Systems). Measurement of plasma 2-ME was per-
formed by PPD Development as previously described (37). Outliers 
were identified using the ROUT method (robust regression and outlier 
removal method in GraphPad Prism 6, ref. 93); 7 outliers in the con-
trol group and 6 outliers in the PE group were identified, subsequently 
excluded from the data presented, and statistically analyzed, as shown 
in Supplemental Figure 5B. Human placenta biopsies were obtained 
from patients who were delivered at Brigham and Women’s Hospital 
(patients of TFM). Placental glycogen content was quantified by the 
tissue digestion method described above.
Statistics. Data are presented as mean ± SD or SEM, as indicated 
in the figure legends. Unpaired 2-tailed t test with Welch’s correc-
tion, Mann-Whitney U test, or 1-way ANOVA with Tukey’s multi-
ple comparisons test was used as appropriate and specified in the 
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